OOIR: Observatory of International Research

Papers

(The H4-Index of RMD Open is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
CD73^low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies	204
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism	100
Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	91
Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study	72
Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use	68
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry	60
Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	55
Concordance and agreement between different activity scores in polymyalgia rheumatica	53
Declaration on the use of social media for rheumatology professionals	53
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan	50
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis	49
Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis	48
Optical coherence tomography angiography detects retinal microvascular changes in giant cell arteritis: the potential protective role of aortitis	47
Antirheumatic treatment, disease activity and risk ofStaphylococcus aureusbacteraemia in rheumatoid arthritis: a nationwide nested case–control study	47
PD1 ⁺ TIGIT ⁺ CD4 ⁺ T cells predict response to	46
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination	45
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cr	44
Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study	43
Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry	43
Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review	43
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study	42
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 tri	41
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study	41
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study	41
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupu	41

Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study	40
History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis	40
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis	40
Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation	39
Bilateral swelling of the salivary glands and sicca symptoms: an unusual differential diagnosis—Kimura’s disease, a rare allergic condition with a high IgE serum level—a case report and review of the	38
Machine learning using genotype and gene-expression data identifies alterations of genes involved in infection susceptibility, antigen presentation and cytokine signalling as key contributors to JIA r	38
Engagement and attrition with eHealth tools for remote monitoring in chronic arthritis: a systematic review and meta-analysis	37
Patient-tailored training programme on cardiorespiratory fitness, trunk strength and mobility leads to significantly better outcomes in individuals with axial spondyloarthritis	37
Biomechanical determinants of rheumatoid arthritis severity and excess cardiovascular disease: common origins of two complex diseases	36
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance	36
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies	36
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment	36
Different rheumatoid factor binding patterns distinguish between Sjögren’s disease with or without associated RA	36